Nov. 18, 2026 – SS Innovations International, Inc. (Ticker: SSII) disclosed in a U.S. Securities and Exchange Commission (SEC) Form 4 filing Thursday that its Director, Chairman, Chief Executive Officer and 10% beneficial owner Sudhir Srivastava purchased approximately $300,000 worth of the company’s common stock on Nov. 17, 2026. The open-market purchase was executed at an average per-share price of $2.15, adding 139,535 shares to Srivastava’s personal holdings, which now stand at more than 4.2 million SSII shares, per filing details. Footnotes to the Form 4 confirm the purchase was voluntary, with no mandatory holding requirements, compensation triggers, or pre-arranged trading plan tied to the transaction.

A Florida-based global medtech firm founded by Srivastava in 2018, SS Innovations specializes in the design, manufacturing and commercialization of accessible robotic surgical platforms for minimally invasive procedures. Its flagship SSI Mantra system, which received FDA clearance in 2024 for use in general, urologic, gynecologic and thoracic surgeries, is marketed as a lower-cost alternative to market leader Intuitive Surgical’s da Vinci system, with active deployments across 12 countries including the U.S., India and 11 EU member states. The company went public via a SPAC merger in late 2023, and as of Nov. 17’s market close, held a market capitalization of roughly $128 million. Earlier this month, SSII reported 32% year-over-year revenue growth for Q3 2026, driven by a 27% rise in system placements and 41% growth in recurring instrument and service revenue over the same period in 2025.

Insider purchase activity from top executives is closely monitored by market participants, as senior leadership holds the most granular, real-time visibility into a company’s unannounced operational performance, pipeline progress and long-term strategic outlook. For Srivastava, who has led SSII since its inception and already holds a 10% ownership stake, the purchase signals multiple potential takeaways for investors. First, SSII shares are down 28% year-to-date as of Nov. 17, underperforming the broader S&P 500 Medtech Index’s 11% gain over the same window, suggesting Srivastava may view the current share price as a favorable entry point for personal investment. Second, the purchase comes just two weeks after SSII announced a multi-system distribution agreement with India’s largest private hospital network, a deal management projected during its Q3 earnings call would drive 20%+ system placement growth in the South Asian market in 2027. Incremental purchases from founders and top executives also typically serve to align leadership’s financial incentives more closely with ordinary shareholders, a signal that can boost confidence in the company’s long-term trajectory among existing investors.

Market analysts caution against overinterpreting a single insider transaction, noting that executive purchases can be motivated by personal portfolio planning decisions unrelated to near-term company performance, and past insider buys have not consistently preceded share price gains. SSII also faces material headwinds that investors should weigh alongside the transaction, including intensifying competition in the $18 billion global robotic surgery market, ongoing supply chain constraints for high-value semiconductor components used in its Mantra systems, and a recently announced three-month delay in its FDA submission for expanded pediatric surgery clearance for the Mantra platform, originally planned for Q4 2026.

As of midday trading Thursday, SSII shares were up 3.2% following the disclosure of Srivastava’s purchase, outperforming the flat performance of the broader S&P 500. All insider trading disclosures for U.S.-listed public companies are accessible to the public via the SEC’s EDGAR database, and investors are advised to review a full range of company fundamentals, market conditions and risk factors when evaluating investment decisions, rather than relying exclusively on insider trading activity.

Market commentary for information only — not financial advice.